



Clinical trial results:

A Comparison of LY2605541 versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with 2 or more Oral Antihyperglycemic Medications: An Open-Label, Randomized Study.

Summary

EudraCT number	2012-003941-13
Trial protocol	HU CZ ES DE PL
Global end of trial date	28 May 2014

Results information

Result version number	v1 (current)
This version publication date	02 April 2018
First version publication date	02 April 2018

Trial information

Trial identification

Sponsor protocol code	I2R-MC-BIAK
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01790438
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 12143

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States,
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-285-4559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 May 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	28 May 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to compare LY2605541 and human insulin NPH using the following measures for participants treated for up to 26 weeks:

- Change in participants' overall blood sugar control
- The number of night time low blood sugar episodes
- The number of participants that reach blood sugar targets without low night time blood sugar episodes
- The total number of low blood sugar episodes reported

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 March 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 172
Country: Number of subjects enrolled	Hungary: 35
Country: Number of subjects enrolled	Czech Republic: 35
Country: Number of subjects enrolled	Mexico: 32
Country: Number of subjects enrolled	Puerto Rico: 65
Country: Number of subjects enrolled	Canada: 38
Country: Number of subjects enrolled	Argentina: 45
Country: Number of subjects enrolled	Poland: 56
Country: Number of subjects enrolled	Spain: 45
Country: Number of subjects enrolled	Germany: 45
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 73
Worldwide total number of subjects	641
EEA total number of subjects	216

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	436
From 65 to 84 years	203
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

No text entered.

Pre-assignment

Screening details:

No text entered.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	LY2605541
------------------	-----------

Arm description:

Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose was 10 units and was adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 was given alone or in combination with up to 3 pre-study oral antihyperglycemic medications [OAM(s)] whose use was not excluded in combination with insulin. Treatment may have lasted up to 26 weeks.

Arm type	Experimental
Investigational medicinal product name	LY2605541
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on Fasting Blood Glucose (FBG).

Arm title	Human Insulin NPH
------------------	-------------------

Arm description:

Administered by SC injection once daily at bedtime. Initial dose was 10 units and was adjusted weekly based on FBG. Human insulin isophane suspension (NPH) was used alone or in combination with up to 3 pre-study OAM(s) whose use was not excluded in combination with insulin. Treatment may have lasted up to 26 weeks. Some participants who were unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may have been asked to add a second injection prior to the morning meal.

Arm type	Active comparator
Investigational medicinal product name	Human Insulin NPH
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered by SC injection once daily at bedtime. Initial dose was 10 units and was adjusted weekly based on FBG.

Number of subjects in period 1	LY2605541	Human Insulin NPH
Started	428	213
Received at Least One Dose of Study Drug	427	212
Completed	393	202
Not completed	35	11
Adverse event, serious fatal	4	-
Consent withdrawn by subject	13	2
Physician decision	3	1
Adverse event, non-fatal	3	2
Sponsor Decision	-	3
Lost to follow-up	5	2
Protocol Required Discontinuation	7	1

Baseline characteristics

Reporting groups

Reporting group title	LY2605541
-----------------------	-----------

Reporting group description:

Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose was 10 units and was adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 was given alone or in combination with up to 3 pre-study oral antihyperglycemic medications [OAM(s)] whose use was not excluded in combination with insulin. Treatment may have lasted up to 26 weeks.

Reporting group title	Human Insulin NPH
-----------------------	-------------------

Reporting group description:

Administered by SC injection once daily at bedtime. Initial dose was 10 units and was adjusted weekly based on FBG. Human insulin isophane suspension (NPH) was used alone or in combination with up to 3 pre-study OAM(s) whose use was not excluded in combination with insulin. Treatment may have lasted up to 26 weeks. Some participants who were unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may have been asked to add a second injection prior to the morning meal.

Reporting group values	LY2605541	Human Insulin NPH	Total
Number of subjects	428	213	641
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	58.86	59.79	
standard deviation	± 9.76	± 10.10	-

Gender categorical			
Units: Subjects			
Female	209	107	316
Male	219	106	325

Ethnicity (NIH/OMB)			
Participants who were not located in the United States were reported in the "Unknown or Not Reported" category for ethnicity.			

Units: Subjects			
Hispanic or Latino	148	73	221
Not Hispanic or Latino	195	105	300
Unknown or Not Reported	85	35	120

Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	1	0	1
Asian	53	25	78
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	27	9	36
White	345	178	523
More than one race	0	1	1
Unknown or Not Reported	2	0	2

Body Mass Index (BMI)			
Body mass index is an estimate of body fat based on body weight divided by height squared.			
Units: kilograms/square meters (kg/m^2)			

arithmetic mean	30.80	31.04	
standard deviation	± 5.57	± 5.03	-
Duration of Diabetes			
Units: years			
arithmetic mean	10.87	11.40	
standard deviation	± 6.46	± 7.01	-

End points

End points reporting groups

Reporting group title	LY2605541
-----------------------	-----------

Reporting group description:

Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose was 10 units and was adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 was given alone or in combination with up to 3 pre-study oral antihyperglycemic medications [OAM(s)] whose use was not excluded in combination with insulin. Treatment may have lasted up to 26 weeks.

Reporting group title	Human Insulin NPH
-----------------------	-------------------

Reporting group description:

Administered by SC injection once daily at bedtime. Initial dose was 10 units and was adjusted weekly based on FBG. Human insulin isophane suspension (NPH) was used alone or in combination with up to 3 pre-study OAM(s) whose use was not excluded in combination with insulin. Treatment may have lasted up to 26 weeks. Some participants who were unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may have been asked to add a second injection prior to the morning meal.

Primary: Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c)

End point title	Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c)
-----------------	--

End point description:

Glycosylated hemoglobin A1c (HbA1c) is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. Least Squares (LS) means were calculated by mixed model repeated measures (MMRM) using treatment, stratification factors (country, sulfonylureas/meglitinide use [Yes/No]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable HbA1c data.

End point type	Primary
----------------	---------

End point timeframe:

Baseline, 26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	420	212		
Units: percentage of HbA1c				
least squares mean (standard error)	-1.73 (± 0.04)	-1.36 (± 0.06)		

Statistical analyses

Statistical analysis title	HbA1c statistical analysis
Comparison groups	LY2605541 v Human Insulin NPH

Number of subjects included in analysis	632
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	Least Square Mean Difference
Point estimate	-0.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	-0.23

Secondary: 30-Day Adjusted Rate of Total and Nocturnal Hypoglycemic Events

End point title	30-Day Adjusted Rate of Total and Nocturnal Hypoglycemic Events
-----------------	---

End point description:

Hypoglycemic episodes are defined as an event which is associated with reported signs and symptoms of hypoglycemia, and/or a documented blood glucose (BG) concentration of ≤ 70 milligram per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]). A nocturnal hypoglycemic event is defined as any total hypoglycemia event that occurred between bedtime and waking. Group mean rates of total and nocturnal hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models with treatment, baseline sulfonylurea/meglitinide use, baseline event rate of the corresponding hypoglycemia as covariates, log (exposure/30 days) as the offset in the model. Group Mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable hypoglycemic data.

End point type	Secondary
End point timeframe:	
Baseline through 26 Weeks	

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	425	212		
Units: episodes per participant per 30 days				
arithmetic mean (standard error)				
Total	1.46 (\pm 0.09)	1.73 (\pm 0.13)		
Nocturnal	0.31 (\pm 0.04)	0.61 (\pm 0.07)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With HbA1c $\leq 6.5\%$ and $< 7.0\%$

End point title	Percentage of Participants With HbA1c ≤6.5% and <7.0%
End point description:	
Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.	
Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable HbA1c data.	
End point type	Secondary
End point timeframe:	
26 Weeks	

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	420	212		
Units: Percentage of Participants				
number (not applicable)				
HbA1c ≤6.5%	43.4	24.1		
HbA1c <7.0%	66.3	44.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Fasting Serum Glucose (FSG) (by Laboratory)

End point title	Fasting Serum Glucose (FSG) (by Laboratory)
End point description:	
LS means were calculated from MMRM using treatment, stratification factors (country, sulfonylureas/meglitinide use [Yes/No]), baseline HbA1c strata [≤8.5% or >8.5%]), visit, treatment-by-visit interaction, and baseline value of the response variable as the fixed effects.	
Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable FSG.	
End point type	Secondary
End point timeframe:	
26 Weeks	

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	422	212		
Units: milligrams per deciliter (mg/dL)				
least squares mean (standard error)	112.61 (± 1.56)	118.60 (± 2.20)		

Statistical analyses

No statistical analyses for this end point

Secondary: Fasting Blood Glucose (FBG) (by Self Monitoring)

End point title	Fasting Blood Glucose (FBG) (by Self Monitoring)
-----------------	--

End point description:

LS means were calculated from MMRM using treatment, stratification factors (country, sulfonylureas/meglitinide use [Yes/No]), baseline HbA1c strata [$\leq 8.5\%$ or $> 8.5\%$]), visit, treatment-by-visit interaction, and baseline value of the response variable as the fixed effects.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable FBG data.

End point type	Secondary
----------------	-----------

End point timeframe:

26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	423	209		
Units: milligrams per deciliter (mg/dL)				
least squares mean (standard error)	111.37 (\pm 1.15)	109.75 (\pm 1.60)		

Statistical analyses

No statistical analyses for this end point

Secondary: 6-Point Self-Monitored Blood Glucose (SMBG)

End point title	6-Point Self-Monitored Blood Glucose (SMBG)
-----------------	---

End point description:

6-point SMBG profiles were obtained on 3 nonconsecutive days in the week prior to Weeks 0, 4, 8, 12, 16, and 26. The SMBG measurements were performed while fasting (prior to the morning meal [breakfast]), prior to the midday meal (lunch), prior to the evening meal (dinner), at bedtime, at approximately 0300 hours, and the next day fasting (prior to the morning meal). LS means were calculated by MMRM using treatment, stratification factors (country, sulfonylureas/meglitinide use [Yes/No]), baseline HbA1c strata [$\leq 8.5\%$ or $> 8.5\%$]), visit, treatment-by-visit interaction, and baseline SMBG at the same time point of the response variable as the fixed effects.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable blood glucose data.

End point type	Secondary
----------------	-----------

End point timeframe:

26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	400	204		
Units: mg/dL				
least squares mean (standard error)				
Pre-morning meal (n=400, 203)	111.22 (± 1.15)	109.56 (± 1.61)		
Pre-midday meal (n=396, 202)	123.78 (± 1.75)	133.77 (± 2.44)		
Pre-evening meal (n=392, 204)	130.90 (± 1.75)	146.99 (± 2.41)		
Bedtime (n=383, 199)	144.14 (± 1.96)	159.17 (± 2.72)		
0300 hours (n=372, 192)	116.35 (± 1.55)	117.66 (± 2.15)		
Pre-morning meal the next day (n=400, 204)	110.42 (± 1.18)	109.03 (± 1.65)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline to 26 Weeks in Body Weight

End point title	Change From Baseline to 26 Weeks in Body Weight
-----------------	---

End point description:

LS means were calculated by MMRM using treatment, stratification factors (country, sulfonylureas/meglitinide use [Yes/No]), baseline HbA1c strata [$\leq 8.5\%$ or $>8.5\%$]), visit, treatment-by-visit interaction, and baseline weight as the fixed effects.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable body weight data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, 26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	419	212		
Units: kilograms (kg)				
least squares mean (standard error)	2.02 (± 0.16)	2.34 (± 0.22)		

Statistical analyses

No statistical analyses for this end point

Secondary: HbA1c

End point title	HbA1c
-----------------	-------

End point description:

HbA1c is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. LS means were calculated by MMRM using treatment, stratification factors (country, sulfonyleureas/meglitinide use [Yes/No]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable HbA1c data.

End point type	Secondary
----------------	-----------

End point timeframe:

26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	420	212		
Units: percentage of HbA1c				
least squares mean (standard error)	6.76 (± 0.04)	7.12 (± 0.06)		

Statistical analyses

No statistical analyses for this end point

Secondary: Insulin Dose Per Kilogram (kg) of Body Weight

End point title	Insulin Dose Per Kilogram (kg) of Body Weight
-----------------	---

End point description:

LS means were calculated by MMRM using treatment, stratification factors (country, sulfonyleureas/meglitinide use [Yes/No]), baseline HbA1c strata [$\leq 8.5\%$ or $> 8.5\%$]), visit, and treatment-by-visit interaction as the fixed effects.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable insulin dose and body weight data.

End point type	Secondary
----------------	-----------

End point timeframe:

26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	423	211		
Units: units per kilogram				
least squares mean (standard error)	0.40 (\pm 0.01)	0.35 (\pm 0.02)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Steady-State (Stable Maximum Dose)

End point title	Time to Steady-State (Stable Maximum Dose)
End point description:	
Steady-state was defined as the first local maximum dose (peak dose value) of LY2605541 or human insulin NPH within the window of -2 to +2 weeks. The median time to steady-state of basal insulin dose estimated from Kaplan-Meier analysis was summarized by treatment.	
Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable steady state data.	
End point type	Secondary
End point timeframe:	
Baseline through 26 Weeks	

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	427	212		
Units: weeks				
median (confidence interval 95%)	7.14 (6.57 to 8.14)	5.86 (5.14 to 6.29)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline to 26 Weeks in European Quality of Life - 5 Dimension 3 Levels (EQ-5D-3L) Index

End point title	Change From Baseline to 26 Weeks in European Quality of Life - 5 Dimension 3 Levels (EQ-5D-3L) Index
End point description:	
The EQ-5D-3L is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities,	

pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and extreme problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United States (US) population-based algorithm. The EQ-5D-3L US based index scores ranged from -0.11 to 1.0 where a score of 1.0 indicates perfect health. LS means were calculated from ANCOVA using treatment, stratification factor (country, baseline sulfonylurea sulfonylureas/meglitinide use [Yes/No], baseline HbA1c strata [$\leq 8.5\%$ or $> 8.5\%$]) and baseline value of EQ-5D-3Las covariates.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, 26 Weeks

Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable EQ-5D-3L data. Missing endpoints were imputed with the last observation carried forward (LOCF) method.

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	397	204		
Units: units on a scale				
least squares mean (standard error)	0.02 (\pm 0.01)	0.01 (\pm 0.01)		

Statistical analyses

No statistical analyses for this end point

Secondary: Insulin Treatment Satisfaction Questionnaire (ITSQ) Score

End point title	Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
-----------------	---

End point description:

ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, Insulin Delivery Device. Data presented are the transformed score on a scale of 0-100, higher scores indicate better treatment satisfaction. LS means were calculated using analysis of variance (ANOVA) adjusting for treatment and stratification factors (country, baseline sulfonylureas/meglitinide use [Yes/No], baseline HbA1c [$\leq 8.5\%$ or $> 8.5\%$]).

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable ITSQ data. Missing endpoints were imputed with the LOCF method.

End point type	Secondary
----------------	-----------

End point timeframe:

26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	419	211		
Units: units on a scale				
least squares mean (standard error)	85.04 (± 0.63)	83.84 (± 0.89)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline to 26 Weeks in Adult Low Blood Sugar Survey (LBSS) Scores

End point title	Change From Baseline to 26 Weeks in Adult Low Blood Sugar Survey (LBSS) Scores
-----------------	--

End point description:

Adult LBSS (also referenced as Hypoglycemia Fear Survey - II [HFS-II]) contains 33 items, with each item scored on a 5-point response scale: 0 (never) to 4 (always). Items are categorized in 2 domains: Behavior (or avoidance) with 15 items and Worry (or affect) with 18 items. Sum all the items to obtain a total score (range 0-132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using analysis of covariance (ANCOVA) adjusting for treatment, stratification factor (country, baseline sulfonylureas/meglitinide use [Yes/No]), baseline HbA1c ($\leq 8.5\%$ or $> 8.5\%$), and baseline value of LBSS.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable LBSS data. Missing endpoints were imputed with the LOCF method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, 26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	400	206		
Units: units on a scale				
least squares mean (standard error)	0.53 (± 0.72)	2.05 (± 1.01)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline to 26 Weeks in Lipid Profile

End point title	Change From Baseline to 26 Weeks in Lipid Profile
-----------------	---

End point description:

Lipid profile includes total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides. LS means for post-baseline measures were calculated using MMRM with the fixed effects of stratification factors (baseline HbA1c [$\leq 8.5\%$ and $> 8.5\%$], country, sulfonylureas/meglitinide use, and LDL-C [< 100 mg/dL and ≥ 100 mg/dL], except for the LDL-C outcome variable), visit, treatment, visit-

by-treatment interaction, and baseline value of corresponding lipid outcome variable. LS means for End Of Study measures were calculated using ANCOVA adjusting for stratification factors (baseline HbA1c [$\leq 8.5\%$ and $> 8.5\%$], country, sulfonylureas/meglitinide use, and LDL-C [< 100 mg/dL and ≥ 100 mg/dL] except for the LDL-C outcome variable), treatment, and baseline value of corresponding lipid outcome variable.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, 26 Weeks; Baseline, End Of Study

Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable lipid data. Missing endpoints for End Of Study measures were imputed with the LOCF method

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	420	212		
Units: mg/dL				
least squares mean (standard error)				
Total cholesterol, 26 Weeks	2.08 (\pm 1.42)	2.86 (\pm 2.00)		
Total cholesterol, End Of Study	-0.12 (\pm 1.36)	2.94 (\pm 1.92)		
HDL, 26 Weeks	-0.24 (\pm 0.31)	0.41 (\pm 0.44)		
HDL, End Of Study	0.53 (\pm 0.31)	0.40 (\pm 0.44)		
LDL, 26 Weeks	3.01 (\pm 1.24)	5.90 (\pm 1.74)		
LDL, End Of Study	2.54 (\pm 1.20)	3.89 (\pm 1.69)		
Triglycerides, 26 Weeks	-1.49 (\pm 4.62)	-15.38 (\pm 6.49)		
Triglycerides, End Of Study	-20.34 (\pm 4.79)	-0.45 (\pm 6.74)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Insulin Antibodies

End point title	Percentage of Participants With Insulin Antibodies
-----------------	--

End point description:

The percentage of participants with a positive treatment-emergent anti-LY2605541 antibody response (TEAR) is summarized. TEAR was defined as change from baseline to postbaseline in the anti-LY2605541 antibody level either (1) from undetectable to detectable or (2) from detectable to the value with at least 130% relative increase from baseline. Percentage of participants was calculated by dividing the number of participants with TEAR anytime during the treatment period by the total number of participants analyzed, multiplied by 100.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable anti-drug (LY2605541) antibodies (ADA) data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to 26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	422	212		
Units: percentage of participants				
number (not applicable)	19.7	45.8		

Statistical analyses

No statistical analyses for this end point

Secondary: Intra-Participant Variability in FBG by Standard Deviation

End point title	Intra-Participant Variability in FBG by Standard Deviation
-----------------	--

End point description:

Glucose variability was assessed by between-day variability as measured by the standard deviation of the FBG of the last 7 days prior to the visit using SMBG. LS means were calculated by MMRM using treatment, stratification factors (country, sulfonylureas/meglitinide use [Yes/No], baseline HbA1c strata [$\leq 8.5\%$ or $> 8.5\%$]), visit, treatment-by-visit interaction, and baseline FBG variability as the fixed effects.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable FBG data.

End point type	Secondary
----------------	-----------

End point timeframe:

26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	421	208		
Units: mg/dL				
least squares mean (standard error)	14.44 (± 0.50)	19.07 (± 0.70)		

Statistical analyses

No statistical analyses for this end point

Secondary: Intra-Participant Variability in FBG by the Coefficient of Variation

End point title	Intra-Participant Variability in FBG by the Coefficient of Variation
-----------------	--

End point description:

Glucose variability was assessed by between-day variability as measured by the coefficient of variation of the FBG of the last 7 days prior to the visit using SMBG. LS means were calculated by MMRM using

treatment, stratification factors (country, sulfonylureas/meglitinide use [Yes/No], baseline HbA1c strata [$\leq 8.5\%$ or $> 8.5\%$]), visit, treatment-by-visit interaction, and baseline FBG variability as the fixed effects.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable FBG data.

End point type	Secondary
End point timeframe:	
26 Weeks	

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	421	208		
Units: mg/dL				
least squares mean (standard error)	12.87 (\pm 0.40)	17.05 (\pm 0.56)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Total and Nocturnal Hypoglycemic Events

End point title	Percentage of Participants With Total and Nocturnal Hypoglycemic Events
-----------------	---

End point description:

Hypoglycemic episodes are defined as an event which is associated with reported signs and symptoms of hypoglycemia, and/or a documented blood glucose (BG) concentration of ≤ 70 milligram per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]). A nocturnal hypoglycemic event is defined as any total hypoglycemia event that occurred between bedtime and waking. Percentage of participants was calculated by the number of participants with at least one hypoglycemia divided by the total number of participants analyzed, multiplied by 100.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable hypoglycemic data.

End point type	Secondary
End point timeframe:	
Baseline through 26 Weeks	

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	425	212		
Units: percentage of participants				
number (not applicable)				
Total	76.7	83.5		
Nocturnal	41.6	67.5		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With HbA1c <7.0% and Without Nocturnal Hypoglycemia

End point title	Percentage of Participants With HbA1c <7.0% and Without Nocturnal Hypoglycemia
-----------------	--

End point description:

Hypoglycemic episodes are defined as an event which is associated with reported signs and symptoms of hypoglycemia, and/or a documented blood glucose (BG) concentration of ≤ 70 milligram per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]). A nocturnal hypoglycemic event is defined as any total hypoglycemia event that occurred between bedtime and waking. Percentage of participants was calculated by the number of participants reaching target HbA1c without nocturnal hypoglycemia divided by the total number of participants analyzed, multiplied by 100.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable HbA1c data and hypoglycemia data.

End point type	Secondary
----------------	-----------

End point timeframe:

26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	420	212		
Units: percentage of participants				
number (not applicable)	39.1	12.6		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Injection Site Reactions

End point title	Percentage of Participants With Injection Site Reactions
-----------------	--

End point description:

The percentage of participants with at least one treatment-emergent injection site reaction is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline through 26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	427	212		
Units: percentage of participants				
number (not applicable)	0.7	1.4		

Statistical analyses

No statistical analyses for this end point

Secondary: Rate of Severe Hypoglycemic Events

End point title	Rate of Severe Hypoglycemic Events
-----------------	------------------------------------

End point description:

Hypoglycemic event are defined as an event which is associated with reported signs and symptoms of hypoglycemia, and/or a documented blood glucose (BG) concentration of ≤ 70 milligram per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]). A severe hypoglycemic event was defined as a hypoglycemic episode requiring assistance of another person to actively administer carbohydrates, glucagon, or other resuscitative actions. The hypoglycemia rate per 100 years during a defined period was calculated by the number of hypoglycemia events within the period divided by the number of days participant at risk within the period*36525 days.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable hypoglycemic data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline through 26 Weeks

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	425	212		
Units: events per 100 participant years				
arithmetic mean (standard error)	1.00 (\pm 0.71)	0.00 (\pm 0.00)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Severe Hypoglycemic Events

End point title	Percentage of Participants With Severe Hypoglycemic Events
-----------------	--

End point description:

Hypoglycemic event are defined as an event which is associated with reported signs and symptoms of hypoglycemia, and/or a documented blood glucose (BG) concentration of ≤ 70 milligram per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]). A severe hypoglycemic event was defined as a hypoglycemic episode requiring assistance of another person to actively administer carbohydrates, glucagon, or other resuscitative actions. The percentage of participants with at least one severe hypoglycemia is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable hypoglycemic data.

End point type	Secondary
End point timeframe:	
Baseline through 26 Weeks	

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	425	212		
Units: percentage of participants				
number (not applicable)	0.5	0.0		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline to 26 Weeks in European Quality of Life (EQ-5D-3L) - Visual Analog Scales (VAS) Scores

End point title	Change From Baseline to 26 Weeks in European Quality of Life (EQ-5D-3L) - Visual Analog Scales (VAS) Scores
-----------------	---

End point description:

The EQ-5D-3L is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state.

Analysis Population Description: Participants who received at least one dose of LY2605541 or human insulin NPH with evaluable EuroQol-5D-3L data.

End point type	Secondary
End point timeframe:	
Baseline, 26 Weeks	

End point values	LY2605541	Human Insulin NPH		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	399	206		
Units: units on a scale				
least squares mean (standard error)	2.52 (\pm 0.68)	1.41 (\pm 0.95)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Analysis Period 2 (AP2)

Adverse event reporting additional description:

I2R-MC-BIAK

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

Reporting groups

Reporting group title	LY2605541
-----------------------	-----------

Reporting group description: -

Reporting group title	Human Insulin NPH
-----------------------	-------------------

Reporting group description: -

Serious adverse events	LY2605541	Human Insulin NPH	
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 427 (6.56%)	9 / 212 (4.25%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
glioblastoma			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
malignant peritoneal neoplasm			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
non-hodgkin's lymphoma			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ovarian neoplasm			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
squamous cell carcinoma of skin			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
non-cardiac chest pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
sudden death			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
ulcer			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
uterovaginal prolapse			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
sleep apnoea syndrome			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
depression			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
suicidal ideation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
alanine aminotransferase increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			

fall			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
radius fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
acute myocardial infarction			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
angina unstable			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
atrial flutter			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
atrioventricular block			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac arrest			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
cardiac failure			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac failure congestive			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
coronary artery insufficiency			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
myocardial ischaemia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
carotid artery stenosis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
syncope			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
nausea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pancreatitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
vomiting			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
hepatic cirrhosis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Skin and subcutaneous tissue disorders			
psoriasis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
calculus ureteric			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
intervertebral disc disorder			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
abdominal wall abscess			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
bronchitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cellulitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastrointestinal infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hepatitis c			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
meningitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
pneumonia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
hypoglycaemia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	LY2605541	Human Insulin NPH	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	228 / 427 (53.40%)	111 / 212 (52.36%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
basal cell carcinoma			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
pancreatic neoplasm			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	

Vascular disorders flushing alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
hypertension alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	6 / 427 (1.41%) 6	1 / 212 (0.47%) 1	
hypotension alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	1 / 212 (0.47%) 1	
peripheral arterial occlusive disease alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
thrombophlebitis alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
venous insufficiency alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 1	
Surgical and medical procedures anorectal operation alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 1	
cataract operation alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 2	
colon polypectomy			

alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
coronary artery bypass		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
dental implantation		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
endarterectomy		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
epidural anaesthesia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
medical device removal		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	2	0
nerve block		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
tooth extraction		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	3	0
ureteral stent removal		
alternative dictionary used: MedDRA 16.0		

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences (all)	0	1	
chest discomfort			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
chest pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	2 / 212 (0.94%)	
occurrences (all)	2	2	
chills			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
fatigue			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	5 / 212 (2.36%)	
occurrences (all)	1	5	
influenza like illness			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
injection site hypertrophy			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
injection site nodule			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
injection site pain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
injection site rash		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
malaise		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
non-cardiac chest pain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
oedema		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	2	0
oedema peripheral		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	11 / 427 (2.58%)	3 / 212 (1.42%)
occurrences (all)	14	3
pain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	2 / 212 (0.94%)
occurrences (all)	1	2
pyrexia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0

spinal pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 3	0 / 212 (0.00%) 0	
vessel puncture site bruise alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
vessel puncture site pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
Immune system disorders allergy to arthropod bite alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
food allergy alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
hypersensitivity alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
multiple allergies alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 2	
seasonal allergy alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
Reproductive system and breast disorders			

cervical dysplasia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
dysmenorrhoea alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
erectile dysfunction alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders asthma alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	0 / 212 (0.00%) 0	
cough alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	11 / 427 (2.58%) 12	11 / 212 (5.19%) 11	
dyspnoea alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 3	0 / 212 (0.00%) 0	
nasal congestion alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	0 / 212 (0.00%) 0	
oropharyngeal pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	8 / 427 (1.87%) 8	4 / 212 (1.89%) 5	
productive cough alternative dictionary used:			

MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
respiratory tract congestion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	2 / 212 (0.94%)	
occurrences (all)	2	2	
rhinitis allergic			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences (all)	1	1	
rhinorrhoea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
depression			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 427 (0.70%)	1 / 212 (0.47%)	
occurrences (all)	3	1	
insomnia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences (all)	1	1	
nervousness			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences (all)	0	1	
psychogenic seizure			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
sleep disorder			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
Investigations			
alanine aminotransferase increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	6 / 427 (1.41%)	2 / 212 (0.94%)	
occurrences (all)	8	2	
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 427 (0.94%)	2 / 212 (0.94%)	
occurrences (all)	6	2	
biopsy thyroid gland			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
blood alkaline phosphatase increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
blood creatine phosphokinase increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	2 / 212 (0.94%)	
occurrences (all)	1	2	
blood creatinine increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)	
occurrences (all)	2	0	
blood pressure increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
blood triglycerides increased			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	2	0
blood urine present		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
electrocardiogram t wave inversion		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
hepatic enzyme increased		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	2 / 212 (0.94%)
occurrences (all)	1	2
protein urine present		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
transaminases increased		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
weight increased		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	14 / 427 (3.28%)	5 / 212 (2.36%)
occurrences (all)	15	5
white blood cell count decreased		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
white blood cell count increased		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1

Injury, poisoning and procedural complications			
animal bite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences (all)	0	1	
animal scratch			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
ankle fracture			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 427 (0.70%)	0 / 212 (0.00%)	
occurrences (all)	3	0	
arthropod bite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences (all)	1	1	
arthropod sting			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
back injury			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences (all)	0	1	
bone fissure			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
contusion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 427 (0.94%)	1 / 212 (0.47%)	
occurrences (all)	4	1	
epicondylitis			
alternative dictionary used:			

MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
eye contusion		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	2	0
fall		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	2 / 212 (0.94%)
occurrences (all)	0	2
foot fracture		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
injury		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
joint injury		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
laceration		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	2	0
ligament sprain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	5 / 427 (1.17%)	0 / 212 (0.00%)
occurrences (all)	5	0
limb crushing injury		
alternative dictionary used: MedDRA 16.0		

subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
limb injury		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	1 / 212 (0.47%)
occurrences (all)	2	1
muscle strain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
skin injury		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
spinal compression fracture		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
stab wound		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
stress fracture		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
tendon rupture		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
thermal burn		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0

tooth fracture alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
upper limb fracture alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
Congenital, familial and genetic disorders type iv hyperlipidaemia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	0 / 212 (0.00%) 0	
type v hyperlipidaemia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 3	0 / 212 (0.00%) 0	
Cardiac disorders atrial fibrillation alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	0 / 212 (0.00%) 0	
bundle branch block right alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	0 / 212 (0.00%) 0	
coronary artery disease alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	2 / 212 (0.94%) 2	
coronary artery stenosis alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
myocardial ischaemia			

<p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p>	
<p>tachycardia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p>	<p>1 / 212 (0.47%)</p> <p>1</p>	
<p>ventricular extrasystoles</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>2</p>	<p>1 / 212 (0.47%)</p> <p>1</p>	
<p>Nervous system disorders</p> <p>balance disorder</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>convulsion</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dementia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>diabetic neuropathy</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dizziness</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dysgeusia</p> <p>alternative dictionary used: MedDRA 16.0</p>	<p>0 / 427 (0.00%)</p> <p>0</p> <p>0 / 427 (0.00%)</p> <p>0</p> <p>1 / 427 (0.23%)</p> <p>1</p> <p>1 / 427 (0.23%)</p> <p>1</p> <p>4 / 427 (0.94%)</p> <p>4</p>	<p>1 / 212 (0.47%)</p> <p>1</p> <p>1 / 212 (0.47%)</p> <p>1</p> <p>0 / 212 (0.00%)</p> <p>0</p> <p>7 / 212 (3.30%)</p> <p>8</p>	

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	2	0
headache		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	23 / 427 (5.39%)	9 / 212 (4.25%)
occurrences (all)	30	17
hypoaesthesia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	6 / 427 (1.41%)	0 / 212 (0.00%)
occurrences (all)	6	0
neuralgia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
paraesthesia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	3 / 427 (0.70%)	0 / 212 (0.00%)
occurrences (all)	3	0
polyneuropathy		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
presyncope		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
sensory loss		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
sinus headache		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0

speech disorder alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
syncope alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	1 / 212 (0.47%) 1	
tension headache alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
transient global amnesia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	0 / 212 (0.00%) 0	
viith nerve paralysis alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 1	
Blood and lymphatic system disorders			
anaemia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	4 / 427 (0.94%) 4	0 / 212 (0.00%) 0	
hypochromic anaemia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 1	
leukocytosis alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 1	
monocytosis alternative dictionary used: MedDRA 16.0			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>thrombocytopenia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p> <p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p> <p>0 / 212 (0.00%)</p> <p>0</p>	
<p>Ear and labyrinth disorders</p> <p>deafness unilateral</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ear pain</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>meniere's disease</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>tinnitus</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>vertigo</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p> <p>0 / 427 (0.00%)</p> <p>0</p> <p>1 / 427 (0.23%)</p> <p>1</p> <p>1 / 427 (0.23%)</p> <p>1</p> <p>3 / 427 (0.70%)</p> <p>3</p>	<p>0 / 212 (0.00%)</p> <p>0</p> <p>1 / 212 (0.47%)</p> <p>1</p> <p>0 / 212 (0.00%)</p> <p>0</p> <p>2 / 212 (0.94%)</p> <p>2</p> <p>0 / 212 (0.00%)</p> <p>0</p>	
<p>Eye disorders</p> <p>conjunctivitis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>diabetic retinal oedema</p> <p>alternative dictionary used: MedDRA 16.0</p>	<p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p>	

subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
eye allergy		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
eye pain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
eye pruritus		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
glaucoma		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
panophthalmitis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
retinal artery occlusion		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
retinopathy hypertensive		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
scleritis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0

vision blurred alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 2	0 / 212 (0.00%) 0	
Gastrointestinal disorders			
abdominal discomfort alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	1 / 212 (0.47%) 1	
abdominal distension alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	4 / 427 (0.94%) 4	0 / 212 (0.00%) 0	
abdominal pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	1 / 427 (0.23%) 1	2 / 212 (0.94%) 3	
abdominal pain lower alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 3	1 / 212 (0.47%) 1	
abdominal pain upper alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	2 / 427 (0.47%) 2	3 / 212 (1.42%) 3	
anal pruritus alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 1	
colitis ulcerative alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	0 / 427 (0.00%) 0	1 / 212 (0.47%) 1	
constipation alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	2 / 212 (0.94%)
occurrences (all)	1	2
dental caries		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
diarrhoea		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	13 / 427 (3.04%)	6 / 212 (2.83%)
occurrences (all)	16	9
dry mouth		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
dyspepsia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	5 / 212 (2.36%)
occurrences (all)	2	8
epigastric discomfort		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
gastric ulcer		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
gastritis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
gastrointestinal disorder		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	2

gastroesophageal reflux disease		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
gingival inflammation		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
impaired gastric emptying		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
irritable bowel syndrome		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
mouth ulceration		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
nausea		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	6 / 427 (1.41%)	3 / 212 (1.42%)
occurrences (all)	6	5
pancreatic steatosis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
swollen tongue		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
toothache		
alternative dictionary used: MedDRA 16.0		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>vomiting</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 427 (1.41%)</p> <p>6</p> <p>5 / 427 (1.17%)</p> <p>5</p>	<p>0 / 212 (0.00%)</p> <p>0</p> <p>3 / 212 (1.42%)</p> <p>3</p>	
<p>Hepatobiliary disorders</p> <p>cholelithiasis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p>	
<p>Skin and subcutaneous tissue disorders</p> <p>blister</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dermal cyst</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dermatitis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dermatitis contact</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dermatosis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ecchymosis</p> <p>alternative dictionary used: MedDRA 16.0</p>	<p>1 / 427 (0.23%)</p> <p>1</p> <p>1 / 427 (0.23%)</p> <p>1</p> <p>1 / 427 (0.23%)</p> <p>2</p> <p>1 / 427 (0.23%)</p> <p>2</p> <p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p> <p>0 / 212 (0.00%)</p> <p>0</p> <p>0 / 212 (0.00%)</p> <p>0</p> <p>1 / 212 (0.47%)</p> <p>1</p> <p>1 / 212 (0.47%)</p> <p>1</p>	

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
heat rash			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
hyperhidrosis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	2 / 212 (0.94%)	
occurrences (all)	1	2	
lipohypertrophy			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	3 / 212 (1.42%)	
occurrences (all)	1	4	
pruritus			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	1 / 212 (0.47%)	
occurrences (all)	2	1	
rash			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 427 (0.94%)	3 / 212 (1.42%)	
occurrences (all)	4	3	
urticaria			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 427 (0.70%)	0 / 212 (0.00%)	
occurrences (all)	3	0	
Renal and urinary disorders			
bladder spasm			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences (all)	0	1	
diabetic nephropathy			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences (all)	1	1	
dysuria			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences (all)	0	1	
hydronephrosis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
pollakiuria			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
renal cyst			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences (all)	0	1	
renal failure			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences (all)	2	1	
urinary retention			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
Endocrine disorders			
hypogonadism			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
hypothyroidism			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences (all)	1	1	
Musculoskeletal and connective tissue disorders			
ankylosing spondylitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)	
occurrences (all)	0	1	
arthralgia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 427 (0.70%)	6 / 212 (2.83%)	
occurrences (all)	3	7	
arthritis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 427 (0.70%)	0 / 212 (0.00%)	
occurrences (all)	3	0	
back pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	16 / 427 (3.75%)	8 / 212 (3.77%)	
occurrences (all)	17	10	
bursitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)	
occurrences (all)	2	0	
flank pain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	1 / 212 (0.47%)	
occurrences (all)	2	1	
joint effusion			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
muscle spasms			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	3 / 427 (0.70%)	1 / 212 (0.47%)
occurrences (all)	3	1
muscle swelling		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
musculoskeletal chest pain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
musculoskeletal pain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	6 / 427 (1.41%)	0 / 212 (0.00%)
occurrences (all)	6	0
musculoskeletal stiffness		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
myalgia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	4 / 427 (0.94%)	2 / 212 (0.94%)
occurrences (all)	4	3
myositis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	2
neck pain		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	2 / 212 (0.94%)
occurrences (all)	2	2
osteoarthritis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	2 / 212 (0.94%)
occurrences (all)	2	2

<p>pain in extremity</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>11 / 427 (2.58%)</p> <p>11</p>	<p>3 / 212 (1.42%)</p> <p>6</p>	
<p>synovial cyst</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p>	
<p>tendonitis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p>	
Infections and infestations			
<p>bone abscess</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p>	
<p>bronchitis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 427 (1.87%)</p> <p>8</p>	<p>4 / 212 (1.89%)</p> <p>4</p>	
<p>cellulitis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 427 (0.70%)</p> <p>4</p>	<p>0 / 212 (0.00%)</p> <p>0</p>	
<p>conjunctivitis infective</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 427 (0.23%)</p> <p>1</p>	<p>0 / 212 (0.00%)</p> <p>0</p>	
<p>cystitis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 427 (0.70%)</p> <p>4</p>	<p>1 / 212 (0.47%)</p> <p>1</p>	
<p>dengue fever</p> <p>alternative dictionary used: MedDRA 16.0</p>			

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
diverticulitis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
ear infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
eye infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	2	0
fungus infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
furuncle		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	5	0
gastroenteritis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	3 / 427 (0.70%)	1 / 212 (0.47%)
occurrences (all)	4	1
gastroenteritis viral		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	2 / 212 (0.94%)
occurrences (all)	1	2
helicobacter infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0

herpes simplex		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
herpes zoster		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	3 / 212 (1.42%)
occurrences (all)	2	3
hordeolum		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
influenza		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	7 / 427 (1.64%)	7 / 212 (3.30%)
occurrences (all)	8	8
laryngitis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
lower respiratory tract infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
nail infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
nasopharyngitis		
alternative dictionary used: MedDRA 16.0		

subjects affected / exposed	29 / 427 (6.79%)	23 / 212 (10.85%)
occurrences (all)	39	34
oral herpes		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	2
otitis externa		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)
occurrences (all)	1	1
paronychia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
pharyngitis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	1 / 212 (0.47%)
occurrences (all)	2	1
pulpitis dental		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	2 / 212 (0.94%)
occurrences (all)	0	2
respiratory tract infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	3 / 427 (0.70%)	0 / 212 (0.00%)
occurrences (all)	3	0
rhinitis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
scarlet fever		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1

sinusitis		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	6 / 427 (1.41%)	5 / 212 (2.36%)
occurrences (all)	7	7
skin infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
soft tissue infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
testicular abscess		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
tooth abscess		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	2 / 212 (0.94%)
occurrences (all)	2	3
tooth infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	5 / 427 (1.17%)	0 / 212 (0.00%)
occurrences (all)	5	0
upper respiratory tract infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	18 / 427 (4.22%)	5 / 212 (2.36%)
occurrences (all)	23	5
urinary tract infection		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	10 / 427 (2.34%)	4 / 212 (1.89%)
occurrences (all)	14	5
vaginitis bacterial		
alternative dictionary used: MedDRA 16.0		

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
varicella			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
viral infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
viral upper respiratory tract infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 427 (0.47%)	1 / 212 (0.47%)	
occurrences (all)	2	1	
wound infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
abnormal loss of weight			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	1 / 212 (0.47%)	
occurrences (all)	1	1	
abnormal weight gain			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 427 (0.70%)	0 / 212 (0.00%)	
occurrences (all)	3	0	
decreased appetite			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)	
occurrences (all)	1	0	
gout			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	2	0
hyperglycaemia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
hypertriglyceridaemia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	5 / 427 (1.17%)	0 / 212 (0.00%)
occurrences (all)	5	0
hyperuricaemia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1
hypokalaemia		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	2	0
obesity		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	2 / 427 (0.47%)	0 / 212 (0.00%)
occurrences (all)	2	0
overweight		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	1 / 427 (0.23%)	0 / 212 (0.00%)
occurrences (all)	1	0
vitamin d deficiency		
alternative dictionary used: MedDRA 16.0		
subjects affected / exposed	0 / 427 (0.00%)	1 / 212 (0.47%)
occurrences (all)	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported